AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04314115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
Study NCT04314115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy and positive psychology
Description: Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
Study NCT02583165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1873
Description: Subjects will receive MEDI1873 by intravenous administration
Study NCT01084824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen and cantharidin
Description: Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
Study NCT01084824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liquid nitrogen and topical placebo
Description: Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
Study NCT04504292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUPREP Bowel Prep Kit
Description: Bowel prep prior to colonoscopy
Study NCT04504292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely Oral Product
Description: Bowel prep prior to colonoscopy
Study NCT02226380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
Study NCT01899417 — intervention group
Intervention type: DEVICE
Intervention: ConforMIS iTotal® Knee Replacement
Description: Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
Study NCT02208518 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopy ultrasound elastography
Description: During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
Study NCT02208518 — intervention group
Intervention type: DEVICE
Intervention: EUS-elastography
Study NCT00314262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib & Celecoxib
Description: Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months.
Study NCT01283282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg PO qday for 6 weeks
Study NCT01283282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo PO qday for 6 weeks
Study NCT00096031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
Study NCT01821391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDL-PDT
Description: Metvix natural daylight photodynamic therapy
Study NCT01973296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED to home care transition
Description: The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
Study NCT01973296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
Study NCT01821391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: c-PDT
Description: Metvix conventional photodynamic therapy
Study NCT01821391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo c-PDT
Description: Metvix placebo conventional photodynamic therapy
Study NCT03371602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
Study NCT03371602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-organ sampling
Description: a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
Study NCT04080362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitralStitch
Description: With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
Study NCT00682006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine
Description: 4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
Study NCT00682006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand washing Soap
Description: Hand washing soap was provided to Mothers through TBAs.
Study NCT00682006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine
Description: 4% Chlorhexidine was provided to be applied by Mothers through TBAs.
Study NCT01429194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACE Stapler
Description: The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
Study NCT00206700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Open Label, 8 week cycle
Study NCT01077908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cellular Therapy
Description: CMV-specific T-cells, single infusion at 27 days post-HSCT
Study NCT01077908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best available antiviral drug therapy
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Study NCT01077908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available antiviral drug therapy
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Study NCT00495573 — intervention group
Intervention type: DRUG
Intervention: acyclovir
Description: 400 mg acyclovir, orally three times a day for 5 days
Study NCT02197819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sling
Study NCT01590628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiCord
Description: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
Study NCT00083226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study NCT02197819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Rotation Brace
Study NCT03234543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
Study NCT03234543 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No Remote ischemic conditioning
Description: Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
Study NCT00684281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurological and neuropsychological consultation, MRI
Description: Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
Study NCT00083226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00684281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA
Description: Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
Study NCT00795262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinapril (Accupril) plus Alpha Lipoic Acid
Description: Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
Study NCT00795262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: accupril, placebo
Description: accupril 40 mg
Study NCT00795262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: accupril, alpha lipoic acid
Description: accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
Study NCT02937727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI compatible and LFP recordable G106R of Beijing Pins medical.
Study NCT03573466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
Study NCT00004578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
Study NCT00004578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 150 mg, every 12 hours
Study NCT00004578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 40 mg every 12 hours
Study NCT03022747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
Study NCT03022747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Oral 6-mercaptopurine and methotrexate
Study NCT00165035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar Paclitaxel Drug Eluting Coronary Stent System
Description: Drug eluting stent
Study NCT00165035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Description: Drug eluting stent
Study NCT01942551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Study NCT01942551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study NCT00538616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
Study NCT00538616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
Study NCT02349802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auto-injector with exenatide suspension
Description: A flexible study design to accommodate multiple cohorts.
Study NCT02349802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syringe with exenatide suspension
Description: A flexible study design to accommodate multiple cohorts.
Study NCT03301350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
Study NCT03301350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study NCT03301350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study NCT03469713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab).
Study NCT05687240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong/Tai Chi
Description: Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
Study NCT05687240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance.
Study NCT01746225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
Study NCT04393168 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lymphatic clearance measurement
Description: The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
Study NCT02168218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7-day overfeeding
Description: 7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
Study NCT02168218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day overfeeding
Description: 7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
Study NCT02969356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
Study NCT02969356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSC
Description: The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
Study NCT00769912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% N2O- 50%O2 mixture
Description: 50% N2O- 50%O2 mixture administration
Study NCT00769912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (air)
Description: Placebo administration during the intervention
Study NCT00302211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost (5 μg)
Description: iloprost inhalation solution (Ventavis) (5 μg)
Study NCT00302211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Placebo
Description: inhaled placebo
Study NCT00302211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: inhaled placebo
Study NCT00302211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral sildenafil (dosage between 60 and 300 mg/day)
Study NCT00302211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: oral sildenafil (dosage between 60 and 300 mg/day)
Study NCT00302211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: oral bosentan (dosage between 62.5 and 125 mg BID)
Study NCT00302211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bosentan
Description: oral bosentan (dosage between 62.5 and 125 mg BID)
Study NCT00751803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA Low Dose
Study NCT00751803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eletriptan
Study NCT00751803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00751803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00751803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00751803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA Medium Dose
Study NCT03186027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 plus NADH
Description: Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect
Study NCT03186027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phosphoserine plus vitamin C
Description: Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo
Study NCT02452424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 capsules, 200 mg
Study NCT02452424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, IV
Study NCT03612167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive intervention
Description: a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
Study NCT03612167 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional group
Description: 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
Study NCT03222375 — intervention group
Intervention type: DEVICE
Intervention: SQUED™ series 28.1 home-use
Description: Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!
Study NCT03871127 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Using sirolimus eluting stent
Study NCT03871127 — intervention group
Intervention type: PROCEDURE
Intervention: coronary artery bypass graft
Description: coronary artery bypass graft
Study NCT04695938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
Study NCT02150564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonowand
Description: Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure